Real-time PCR assays and Western blot analysis confirmed that FOXA1 expression is reduced in post-treatment (PT) samples compared to non-small cell lung cancer (NSCLC) tissues. This evidence concerns the gene FOXA1 and non-small cell lung carcinoma.